Sebastian Nikhil T, Xu-Welliver Meng, Williams Terence M
Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, OH, USA.
J Thorac Dis. 2018 Aug;10(Suppl 21):S2451-S2464. doi: 10.21037/jtd.2018.04.52.
The standard-of-care treatment for early-stage non-small cell lung cancer (NSCLC) continues to be surgery in the form of lobectomy or pneumonectomy. Stereotactic body radiation therapy (SBRT) has evolved as a viable alternative to surgery for medically inoperable patients, achieving excellent local control (LC) with relatively minimal toxicity in standard-risk patients. Nevertheless, the maturation of SBRT has fostered debate regarding its use, technique, dose, and fractionation, particularly in the context of patient- and disease-specific characteristics such as tumor size and location. This review will cover the recent trends and future directions of SBRT as it becomes an increasingly individualized modality in the treatment of early-stage NSCLC.
早期非小细胞肺癌（NSCLC）的标准治疗方法仍然是以肺叶切除术或全肺切除术形式进行的手术。立体定向体部放射治疗（SBRT）已发展成为无法进行手术的患者的一种可行替代方案，在标准风险患者中以相对较低的毒性实现了出色的局部控制（LC）。然而，SBRT的成熟引发了关于其使用、技术、剂量和分割方式的争论，特别是在考虑肿瘤大小和位置等患者和疾病特定特征的背景下。随着SBRT在早期NSCLC治疗中变得越来越个体化，本综述将涵盖其近期趋势和未来方向。
